Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 10

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 10
---
 value was destroyed, with the stock price falling 63.9%.                                                                                                        |

| • |     | Mr. Regan is inexperienced and wholly unqualified to serve as a director of a highly specialized rare                                                                                                                       
 disease company like Zevra. Specifically, we believe that Mr. Regan’s erratic and arguably unprofessional nature, evident in his communications on his personal blog and online posts, would create serious risk to Zevra’s 
 reputation, performance, and momentum if he were elected to the Board.                                                                                                                                                      |

| • |     | Mr. Mangless has also nominated Dr. Mickle, who cannot be considered independent under SEC and stock                                                                                                                                                  
 exchange rules due to his former roles as CEO and President of the Company until his resignation in 2023 and his consulting arrangement with the Company until 2024. While our current management team has delivered a strong 54.8% total stockholder 
 return, Dr. Mickle’s leadership led to stockholder value destruction at Zevra – resulting in the share price plummeting 97.4% during his tenure, substantially underperforming both industry benchmarks and the                                       
 broader market.                                                                                                                                                                                                                                       |

| • |     | Further, it would be highly unusual for a former CEO to serve as a director of that same company, so soon after                                                                                                                                 
 departing as CEO. This could create a scenario where Dr. Mickle seeks to micromanage the executive team instead of focusing on oversight, or even to pursue a return to his previous role as CEO. We view this potential outcome as negative to 
 Zevra and its stockholders, especially given the substantial increase in stockholder value delivered by the current management team, as compared to the destruction of stockholder value under Dr. Mickle’s leadership.                         |

Your Board and management team believe the addition of one or both of Mr. Mangless’ nominees would distract from management’s continued successful execution of our strategic plan. In the absence of any stated strategy or ideas for increasing stockholder value, we believe Mr. Mangless and his nominees will only disrupt the clear progress underway and risk our ability to deliver short- and long-term value for you.

PROTECT THE VALUE OF YOUR INVESTMENT IN ZEVRA:

VOTE THE WHITE PROXY CARD TODAY

Your
Board and management team have a clear path forward to continue delivering value for all Zevra stockholders as we advance the Company’s transformation into a leading rare disease company. Your refreshed Zevra Board is active, engaged,